Findings

What do systematic reviews say?

28 questions · 32 findings · 7 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 15.6%GRADE not reported 0 · 0%Very low 5 · 15.6%Low 10 · 31.3%Moderate 11 · 34.4%High 1 · 3.1%

Oral creatine vs placebo

Change in disability score · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Oral hydroxyurea vs placebo

Change in disability score · children and adults with SMA types II and III

2 findings from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 57 participants
Low
Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Moderate

Intrathecal injected nusinersen vs sham

Change in disability score · children with SMA type II

Intrathecal injected nusinersen probably leads to higher change in disability score compared with sham procedure (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
MD 5.9 [3.7, 8.1]
1 study · 126 participants
Moderate

Oral olesoxime vs placebo

Change in disability score · non‐ambulatory children and adolescents with SMA types II and III

4 findings from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Very low
Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Very low
Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 1.43
1 study · 160 participants
Very low

Show 1 more finding

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Low

Oral phenylbutyrate vs placebo

Change in disability score · children with SMA type II

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Subcutaneous somatotropin vs placebo

Change in disability score · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
19 participants
Very low

Intravenous thyrotropin releasing hormone vs placebo

Change in disability score · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in disability score · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Oral valproic acid vs placebo

Change in disability score · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
31 participants
Low

Oral gabapentin vs placebo

Change in disability score · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Low

Riluzole vs placebo

Change in motor score after two years · children with SMA type I

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy type I 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intrathecal injected nusinersen vs sham

Change in disability score (3 point‐change) · children with SMA type II

Intrathecal injected nusinersen showed no clear difference in change in disability score (3 point‐change) compared with sham procedure (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 1.8 [0.99, 3.1]
1 study · 126 participants
Moderate

IVIg vs prednisolone

Change in mean disability score on Rankin scale · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Moderate

IVIg vs intravenous methylprednisolone

Change in mean disability score on Rankin scale · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

IVIg vs placebo

Change in mean disability score on Rankin scale · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 90 participants
High

IVIg vs plasma exchange

Change in mean disability score on Rankin scale · people with CIDP

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma exchange vs sham exchange

Change in disability Neuropathy Disability Score · people with IgG and IgA paraproteinaemic neuropathy

1 finding from 1 review

Treatment for IgG and IgA paraproteinaemic neuropathy 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Low

IVIg vs prednisolone

Change in mean disability score at 24 weeks or later · people with CIDP

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs intravenous methylprednisolone

Change in mean disability score at 24 weeks or later · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Moderate

IVIg vs placebo

Change in mean disability score at 24 weeks or later · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 117 participants
Moderate